Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Assembly Biosciences (ASMB) EBITDA (2016 - 2025)

Historic EBITDA for Assembly Biosciences (ASMB) over the last 9 years, with Q3 2025 value amounting to -$9.0 million.

  • Assembly Biosciences' EBITDA rose 494.93% to -$9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$38.5 million, marking a year-over-year increase of 541.72%. This contributed to the annual value of -$40.3 million for FY2024, which is 3338.35% up from last year.
  • Assembly Biosciences' EBITDA amounted to -$9.0 million in Q3 2025, which was up 494.93% from -$10.2 million recorded in Q2 2025.
  • Assembly Biosciences' 5-year EBITDA high stood at -$8.9 million for Q1 2025, and its period low was -$60.4 million during Q4 2021.
  • Its 4-year average for EBITDA is -$17.3 million, with a median of -$11.2 million in 2024.
  • As far as peak fluctuations go, Assembly Biosciences' EBITDA crashed by 42112.99% in 2021, and later surged by 5050.91% in 2024.
  • Assembly Biosciences' EBITDA (Quarter) stood at -$60.4 million in 2021, then skyrocketed by 82.17% to -$10.8 million in 2023, then grew by 3.51% to -$10.4 million in 2024, then grew by 13.31% to -$9.0 million in 2025.
  • Its EBITDA stands at -$9.0 million for Q3 2025, versus -$10.2 million for Q2 2025 and -$8.9 million for Q1 2025.